Nymox Lead Drug Shows Positive Effects on Liver Cancer

26 August 2009 (Last Updated August 26th, 2009 18:30)

Nymox Pharmaceutical Corporation has announced that the company's lead development drug, NX-1207, has been shown to significantly reduce hepatocellular carcinoma (HCC) in animals. During experimental studies, the cancers were significantly reduced in size after just two local injections

Nymox Pharmaceutical Corporation has announced that the company's lead development drug, NX-1207, has been shown to significantly reduce hepatocellular carcinoma (HCC) in animals.

During experimental studies, the cancers were significantly reduced in size after just two local injections of NX-1207. The rodents in the studies had transplanted human HCC, a standard model for cancer research.

The company now intends to advance NX-1207 into human clinical trials for the treatment of HCC.

NX-1207 used in these studies is a different formulation and a higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).

NX-1207 is in Phase III development for the treatment of BPH.

The drug has been successful in a series of blinded controlled multi-centre US clinical trials where it has been found to produce improvements that are about double that reported for approved BPH drugs.